Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

ign safety profile in line with our oral presentation at ASCO. As of August 31, 2010 we have completed enrollment of an additional cohort of 10 patients using a fixed, continuous dosing of 560 mg daily. Additionally, the National Cancer Institute (NCI) has dosed the first of 10 pre-typed ABC DLBCL patients. The company has submitted an abstract to the 2010 ASH annual meeting that describes the responses and the duration in all of the CLL/SLL patients dosed to date and we cannot disclose any information contained in the abstract prior to the meeting held in December.
  • Over the last 3 months the company held multiple advisory boards in the US and EU with experts in the field of lymphoma and CLL to obtain feedback to our clinical development plan. We now announce that the company is planning multiple Phase II trials in select B-cell derived malignancies (Mantle Cell in Velcade failure and Velcade naive patients, DLBCL in R-CHOP and transplant failures and CLL combination-safety trials with Bendamustine-Rituxan and Ofatumumab and other investigator initiated trials). Timelines for reportable events and regulatory interactions from these planned Phase II trials will be communicated after the ASH meeting in December.
  • A second Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-45292, is being developed for autoimmune disease; we are on track to complete IND-enabling preclinical safety studies. The company is planning to file an IND by the end of the second quarter of calendar 2011 with this molecule.
  • Factor VIIa Inhibitor, PCI-27483, is a potent and highly selective small molecule inhibitor of coagulation Factor VIIa.  Factor VIIa is best known for its role in triggering the extrinsic pathway of blood coagulation following contact and complex formation with the cell surface glycoprotein Tissue Factor.  Tissue Factor is over-expressed in pancreatic, gastric, lung, breast, colon and many other cancers of epithelial origin. FVIIa In
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... NEWBURY PARK, Calif. , Jan. 22, 2015 ... drive the continued consolidation of localization purchasing in 2015, ... According to a recent study by market ... studied chose a single-source solution for their translation and ...
    (Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Microbiology Testing/Clinical Microbiology Market ... Global Forecast to 2019" report to their ... wide array of techniques for the detection of ...
    (Date:1/22/2015)... Parenteral Drug Association (PDA) today announced the launch of its ... Future. The Manufacturing Science Program SM ... the ongoing focus PDA has on pharmaceutical and biopharmaceutical manufacturing. ... gaps in current manufacturing science as well as gaps that ...
    Breaking Medicine Technology:Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
    (Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
    (Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently delivers ... to have it lead the wedding dress industry into the ... dresses for the global market. , “The CEO of VogueQueen ... focuses on continuing the goal of operational excellence and giving ...
    (Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
    (Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
    (Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
    Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
    ... disease is usually accepted as a hazard of aging, ... are a consequence of aging// or not. Researchers at ... Research Institute have now conducted a study that proves ... Alzheimer's. ,Harmful beta amyloid aggregates accumulate when ...
    ... the number of drug users who completed the treatment for drug ... number of people enrolling// for the treatment in this period. Drug ... had been coerced into it by the criminal justice system than ... a British study of the outcome of treatment for drug addiction, ...
    ... in the American Society, not only among women but also ... under pressure to have a good physique may suffer from ... with weightlifting. ,“Men see these idealized, muscular men ... up,” said Tracy Tylka, author of the study and assistant ...
    ... time for one to undergo an operation.// ,A ... has analysed the outcomes of over 90,000 operations carried out ... best time to have an operation, as they had found ... have published their study in the journal Quality and Safety ...
    ... announced that it will be publishing a peer-reviewed ... is. RESPeRATE, a over-the-counter// therapeutic device that is ... to treat hypertension, the study says. ... (http://www.medscape.com/viewarticle/539099) of Medscape (NASDAQ:WBMD), is authored by William ...
    ... research in mice has found that though they do not ... were able to differentiate the cells// in the sebaceous glands ... how a sebaceous gland is formed. ,In new ... Fuchs, a Howard Hughes Medical Institute investigator at Rockefeller University, ...
    Cached Medicine News:Health News:Aging Critical For Alzheimer's Disease 2Health News:Aging Critical For Alzheimer's Disease 3Health News:Men Take to Unhealthy Practices to be More Muscular 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:New Treatment Mooted For Blood Pressure 2Health News:'Blimp1' Gene Linked To Oily Skin 2
    This optimal design addresses low-cost, simple, non-invasive ankle distraction....
    A straightforward, versatile approach to arthroscopically assisted pin placement in either the ankle or wrist....
    ... The BTA stat Test is ... the qualitative detection of bladder ... diagnosed with bladder cancer. This ... an aid in the management of ...
    ThyroTest by ThyroTec, Inc. is a rapid immunoassay, similar to a rapid pregnancy test. By using 2 drops of blood from a finger stick and 5 drops of diluent, a qualitative TSH level is inicated in min...
    Medicine Products: